Effect of meloxicam and butorphanol on minimum alveolar concentration of isoflurane in rabbits

American Journal of Veterinary Research

Volumn 67, Issue 5, 2006, Pages 770-774

  Turner, Patricia V ^a   Kerr, Carolyn L ^a   Healy, Amanda J ^a   Taylor, W Michael ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUTORPHANOL; CARBON DIOXIDE; ISOFLURANE; MELOXICAM;

ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; CARDIOPULMONARY FUNCTION; CONTROLLED STUDY; DRUG POTENTIATION; END TIDAL CARBON DIOXIDE TENSION; FEMALE; HEART RATE; MINIMUM LUNG ALVEOLUS CONCENTRATION; NONHUMAN; OXYGEN SATURATION; PATCH CLAMP; RABBIT; RECTUM TEMPERATURE; STATISTICAL SIGNIFICANCE;

ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANESTHETICS, INHALATION; ANIMALS; BLOOD PRESSURE; BUTORPHANOL; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HEART RATE; ISOFLURANE; RABBITS; THIAZINES; THIAZOLES;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 33744471897     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.5.770     Document Type: Article

References (28)

1. Budsberg SC, Cross AR, Quandt JE, et al. Evaluation of intravenous administration of meloxicam for perioperative pain management following stifle joint surgery in dogs. Am J Vet Res 2002;63:1557-1563.
2. Eger EI II, Saidman LJ, Brandstater B. Minimum alveolar anaesthetic concentration: a standard of anaesthetic potency. Anesthesiology 1965;26:756-763.
3. Valverde A, Morey TE, Hernandez J, et al. Validation of several types of noxious stimuli for use in determining the minimum alveolar concentration for inhalation anesthetics in dogs and rabbits. Am J Vet Res 2003;64:957-962.
4. Ilkiw JE, Pascoe PJ, Tripp LD. Effects of morphine, butorphanol, buprenorphine, and U50488H on the minimum alveolar concentration of isoflurane in cats. Am J Vet Res 2002; 63:1198-1202.
5. Santos M, Kunkar V, Garcia-Iturralde P, et al. Meloxicam, a specific COX-2 inhibitor, does not enhance the isoflurane minimum alveolar concentration reduction produced by morphine in the rat. Anesth Analg 2004;98:359-363.
6. Sonner JM, Gong D, Li J, et al. Mouse strain modestly influences minimum alveolar concentration and convulsivity of inhaled compounds. Anesth Analg 1999;89:1030-1034.
7. Busch U, Schmid J, Heinzel G, et al. Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab Dispos 1998;26:576-584.
8. Toutain P-L, Raymond N, Laroute V, et al. Pharmacokinetics of meloxicam in plasma and urine of horses. Am J Vet Res 2004; 65:1542-1547.
9. Doherty TJ, Will WA, Rohrbach BW, et al. Effect of morphine and flunixin meglumine on isoflurane minimum alveolar concentration in goats. Vet Anaesth Analg 2004;31:97-101.
10. Quasha AL, Eger EI II, Tinker JH. Determination and applications of MAC. Anesthesiology 1980;53:315-334.
11. Ko JCH, Lange DN, Mandsager RE, et al. Effects of butorphanol and carprofen on the minimum alveolar concentration of isoflurane in dogs. J Am Vet Med Assoc 2000;217:1025-1028.
12. Gomez de Segura IA, Criado AB, Santos M, et al. Aspirin synergistically potentiates isoflurane minimum alveolar concentration reduction produced by morphine in the rat. Anesthesiology 1998;89:1489-1494.
13. Kay-Mugford P, Benn SJ, LaMarre J, et al. In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs. Am J Vet Res 2000;61:802-810.
14. Kam PCA, See AU. Cyclo-oxygenase isoenzymes: physiological and pharmacological role. Anesthesia 2000;55:442-449.
15. Imai A, Steffey EP, Ilkiw JE, et al. Comparison of clinical signs and hemodynamic variables used to monitor rabbits during halothane- and isoflurane-induced anesthesia. Am J Vet Res 1999;60:1189-1195.
16. Gourlay GK, Plummer JL, Cheery DA. Chronopharmacokinetic variability in plasma morphine concentrations following oral doses of morphine solution. Pain 1995;6:375-381.
17. Steffey EP, Baggot JD, Eisele JH, et al. Morphine-isoflurane interaction in dogs, swine and rhesus monkeys. J Vet Pharmacol Ther 1994;17:202-210.
18. Doherty TJ, Geiser DR, Rohrbach BW. Effect of acepromazine and butorphanol on halothane minimum alveolar concentration in ponies. Equine Vet J 1997;29:374-376.
19. Engelhardt G, Homma D, Schlegel K, et al. General pharmacology of meloxicam - part II: effects on blood pressure, blood flow, heart rate, ECG, respiratory minute volume and interactions with paracetamol, pirenzipine, chlorthalidone, phenprocoumon and tolbutamide. Gen Pharmacol 1996;27:679-688.
20. Greene SA, Hartsfield SM, Tyner CL. Cardiovascular effects of butorphanol in halothane-anesthetized dogs. Am J Vet Res 1990;51:1276-1279.
21. Lee JS, Morrow D, Andresen MC, et al. Isoflurane depresses baroreflex control of heart rate in decerebrate rats. Anesthesiology 2002;96:1214-1222.
22. Shekerdemian L, Bohn D. Cardiovascular effects of mechanical ventilation. Arch Dis Child 1999;80:475-480.
23. Pairet M, Van Ryn J, Schierok H, et al. Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4′-isomer. Inflamm Res 1998;47:270-276.
24. Engelhardt G, Homma D, Schnitzler C. Meloxicam: a potent inhibitor of adjuvant arthritis in the Lewis rat. Inflamm Res 1995;44:548-555.
25. Laird JMA, Herrero JF, Garcia de la Rubia P, et al. Analgesic activity of the novel COX-2 preferring NSAID, meloxicam in mono-arthritic rats: central and peripheral components. Inflamm Res 1997;46:203-210.
26. Vivian JA, DeYoung MB, Sumpter TL, et al. kappa-Opioid receptor effects of butorphanol in rhesus monkeys. J Pharmacol Exp Ther 1999;290:259-265.
27. Orti E, Coirini H, Pico JC. Site-specific effects of the non-steroidal anti-inflammatory drug lysine clonixinate on rat brain opioid receptors. Pharmacology 1999;58:190-199.
28. Christie MJ, Vaughan CW, SL Ingram. Opioids, NSAIDs, and 5-lipoxygenase inhibitors act synergistically in brain via arachidonic acid metabolism. Inflamm Res 1999;48:1-4.